Your sector of activity
Genomics research
Clinical and Translational Research
Biopharma & CRO
Our Services
Liquid biopsy
Genome, Exome, Panel
RNA Seq
Methylation
Methylation by sequencing
Methylation using Illumina MethEPIC
Sequencing Only
Genotyping
Nucleic Acid Isolation
Bioinformatics analysis
Tumor Genomic Analysis: Mercury
Gene Expression Analysis: Galileo
Advanced Genomic Analysis Service: GeCo
Constitutional genomic analysis: VarSome Clinical
About us
Our History
Certifications
Board of Directors
Our Management Team
Job Offers
Communication
News
Events
Scientific Publications
Investors
Investor Relations
Annual General Meeting
Financial documents
Financial Communications
Archives
Financial Reports Archives
Archived Press Releases
Liquidity contract
Oncodna friendly takeover bid
Contact
Search
Financial Communications
2025
29/04/2025
Integ
raGen - Annual results 2024
15/01/2025
IntegraGen - 2024 sales and cash position
2024
17/10/2024
IntegraGen - H1 2024 results - Sales up 6% on a like-for-like basis (excluding SeqOIA) and profitability maintained
18/07/2024
IntegraGen - Sales up 6% and cash position of €2.8m
18/04/2024
IntegraGen - 2023 annual results: 5% decline in revenues and positive EBITDA
13/01/2024
IntegraGen - 2023 sales and cash position
2023
19/10/2023
IntegraGen - H1 2023 results - Sales down 13% and resilient profitability
13/07/2023
IntegraGen - First-half 2023 sales of €5.6m, down 13% on H1 2022, and cash position of €4.3m
24/04/2023
IntegraGen - 2022 annual results: 16% revenue growth and positive EBITDA
13/01/2023
IntegraGen - 2022 sales and cash position
2022
18/10/2022
Half-year results 2022 - Strong growth in 35% revenues and improved profitability
13/07/2022
First-half 2022 sales of €6.4m, up +34% on H1 2021, and cash position of €4.5m
29/04/2022
IntegraGen - 2021 annual results: strong 201TP3Q growth in revenues from ongoing operations and marked improvement in profitability
14/01/2022
IntegraGen - 2021 sales and cash position
2021
08/10/2021
IntegraGen - Half-year results 2021
16/07/2021
First-half 2021 sales of €4.8m, up +2% on 2020, and cash position of €4.3m
16/04/2021
Integragen - 2020 annual results: growth in revenues from ongoing operations (+101TP3Q) and EBITDA close to breakeven for the year
12/01/2020
IntegraGen - 2020 sales and cash position
2020
16/11/2020
Successful friendly takeover bid by OncoDNA for IntegraGen shares
18/09/2020
IntegraGen - 1st half 2020 results
09/07/2020
Agreement on a friendly takeover bid by OncoDNA for IIntegraGen
03/04/2020
IntegraGen - Annual results 2019
26/03/2020
IntegraGen announces agreement with leading US cancer center to use MERCURY™
11/03/2020
IntegraGen renews partnership agreement with Institut Pasteur
10/01/2020
IntegraGen - 2019 sales and cash position
Consult the Archives